[DVAX] Dynavax Technologies Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 547.86 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.1 Change: 0.05 (1.23%)
Ext. hours: Change: 0 (0%)

chart DVAX

Refresh chart

Strongest Trends Summary For DVAX

DVAX is in the medium-term down -46% below S&P in 5 months. In the long-term down -73% below S&P in 2 years and down -91% below S&P in 12 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases, and cancer. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a investigational adult hepatitis B vaccine which is in Phase III clinical trials. The company also develops DV1179, a TLR inhibitor of TLR 7 and TLR9 for the treatment of autoimmune and inflammatory diseases that is in Phase I clinical trials; AZD1419, a candidate drug for the treatment of asthma, which is in Phase I clinical trials; SD-101, a second-generation TLR 9 agonist for immunotherapy of cancer that is in Phase I clinical trials; and DV230, an adjuvant platform that is in preclinical studies. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the d

Fundamental Ratios
Shares Outstanding38.5 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -79.43% Sales Growth - Q/Q-72.46% P/E
P/E To EPS Growth P/S67.13 P/BV7.3 Price/Cash Per Share5.61
Price/Free Cash Flow-7.27 ROA-91.91% ROE-137.33% ROI
Current Ratio4.97 Quick Ratio Long Term Debt/Equity Debt Ratio0.27
Gross Margin Operating Margin-1271.85% Net Profit Margin-1263.31% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities140 K Cash From Investing Activities-10.52 M Cash From Operating Activities-24.14 M Gross Profit
Net Profit-26.22 M Operating Profit-26.45 M Total Assets112.17 M Total Current Assets101.98 M
Total Current Liabilities20.5 M Total Debt9.51 M Total Liabilities37.1 M Total Revenue630 K
Technical Data
High 52 week19.95 Low 52 week6.3 Last close6.3 Last change-5.83%
RSI45.23 Average true range0.51 Beta1.08 Volume1.13 M
Simple moving average 20 days-6.96% Simple moving average 50 days-11.86% Simple moving average 200 days-39.2%
Performance Data
Performance Week-20.15% Performance Month-2.02% Performance Quart-43.4% Performance Half-46.56%
Performance Year-61.59% Performance Year-to-date-31.15% Volatility daily5.32% Volatility weekly11.89%
Volatility monthly24.37% Volatility yearly84.41% Relative Volume185.36% Average Volume1.18 M
New High New Low


2019-06-03 16:05:00 | Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference  

2019-06-03 14:15:00 | Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® pembrolizumab; Data Presented Today at the 2019 ASCO Annual Meeting

2019-06-01 14:15:00 | Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® pembrolizumab for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting

2019-05-27 05:00:09 | Dynavax DVAX to Cut Jobs and Focus on Vaccine Business

2019-05-26 17:03:35 | The Week Ahead In Biotech: ASCO Presentations In The Spotlight

2019-05-24 18:10:00 | Here's Why Dynavax Technologies Is Tumbling

2019-05-24 17:41:13 | East Bay biotech pivoted to cancer, found new space — now CEO is leaving, 82 jobs are cut

2019-05-24 07:44:48 | The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

2019-05-23 17:25:00 | Dynavax announces layoffs, CEO retirement

2019-05-23 16:45:00 | Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business

2019-05-21 11:14:54 | Could The Dynavax Technologies Corporation NASDAQ:DVAX Ownership Structure Tell Us Something Useful?

2019-05-10 09:14:00 | Hopeful Signs for These 2 Small Biotech Stocks

2019-05-09 14:08:00 | Why Dynavax Technologies Stock Is Soaring Today

2019-05-09 13:33:33 | Is Dynavax Technologies Corporation DVAX A Good Stock To Buy?

2019-05-09 00:07:24 | Edited Transcript of DVAX earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 21:23:49 | Dynavax Technologies Corp DVAX Q1 2019 Earnings Call Transcript

2019-05-08 19:45:11 | Dynavax Technologies DVAX Reports Q1 Loss, Misses Revenue Estimates

2019-05-08 18:35:47 | Dynavax Technologies: 1Q Earnings Snapshot

2019-05-08 16:05:00 | Dynavax Announces First Quarter 2019 Financial Results

2019-05-08 14:30:00 | Dynavax Technologies Corp. to Host Earnings Call

2019-05-02 17:00:00 | Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® in Adults With End-Stage Renal Disease

2019-05-01 10:33:02 | Analysts Estimate Dynavax Technologies DVAX to Report a Decline in Earnings: What to Look Out for

2019-04-25 16:05:00 | Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8

2019-04-18 16:05:00 | Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019

2019-04-06 10:42:56 | Investors Who Bought Dynavax Technologies NASDAQ:DVAX Shares Three Years Ago Are Now Down 66%

2019-04-03 10:02:41 | After inking lease with cancer-fighting company, this new East Bay biotech project is full

2019-04-02 13:00:00 | Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting

2019-04-02 07:30:37 | The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

2019-03-28 16:05:00 | Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults

2019-03-21 06:30:00 | HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

2019-03-20 16:20:00 | Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019

2019-03-18 16:05:00 | Dynavax Exercises Option for $75 Million in Non-Dilutive Debt

2019-03-07 09:44:00 | Why Dynavax Technologies Cratered in February

2019-03-06 16:05:00 | Dynavax to Present at 39th Annual Cowen Healthcare Conference

2019-03-01 09:00:57 | Should You Be Concerned About Dynavax Technologies Corporation’s NASDAQ:DVAX Historical Volatility?

2019-02-27 03:06:17 | Edited Transcript of DVAX earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 22:40:17 | Dynavax Technologies Corporation DVAX Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:05:00 | Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results

2019-02-12 16:05:00 | Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26

2019-02-11 07:20:00 | Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-10 13:00:00 | Why Dynavax Technologies Stock Marched Higher in January

2019-01-29 16:05:00 | Heather Rowe Named Dynavax’s Vice President of Investor Relations and Corporate Communications

2019-01-16 08:00:00 | Today's Research Reports on Trending Tickers: Dynavax Technologies and Tyme Technologies

2019-01-15 17:00:00 | Why Dynavax Technologies Stock Fell 51% in 2018

2019-01-15 12:18:08 | Is Dynavax Technologies Corporation NASDAQ:DVAX Worth US$10.80 Based On Intrinsic Value?

2019-01-09 10:07:00 | 2 Small-Caps That Should Continue to Stage Comebacks in 2019

2019-01-08 09:00:00 | Sam’s Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® Available to Sam’s Club Patients

2019-01-07 08:17:00 | Here's Why Dynavax Technologies Slid 19% in December

2019-01-03 16:05:00 | Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference

2018-12-30 15:27:08 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials